Journal of Vascular Surgery
Volume 51, Issue 4 , Pages 926-932 , April 2010

Impact of metabolic syndrome on the outcomes of percutaneous renal angioplasty and stenting

Presented at the Thirty-seventh Annual Meeting of the Society for Clinical Vascular Surgery, Fort Lauderdale, Fla, Mar 18-21, 2009.

Received 23 July 2009 ,Accepted 21 September 2009.

References 

  1. Zeller T. Current state of diagnosis and endovascular treatment of renal artery stenosis. Vasa. 2006;35:147–155
  2. Hansen KJ, Cherr GS, Craven TE, Motew SJ, Travis JA, Wong JM, et al. Management of ischemic nephropathy: dialysis-free survival after surgical repair. J Vasc Surg. 2000;32:472–482
  3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA. 2002;287:356–359
  4. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689
  5. Sarafidis PA. Obesity, insulin resistance and kidney disease risk: insights into the relationship. Curr Opin Nephrol Hypertens. 2008;17:450–456
  6. Clavijo LC, Pinto TL, Kuchulakanti PK, Torguson R, Chu WW, Satler LF, et al. Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. Cardiovasc Revasc Med. 2006;7:7–11
  7. Zeller M, Steg PG, Ravisy J, Laurent Y, Janin-Manificat L, L'Huillier I, et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med. 2005;165:1192–1198
  8. Scuteri A, Najjar SS, Muller DC, Andres R, Hougaku H, Metter EJ, et al. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol. 2004;43:1388–1395
  9. Palomo I, Alarcon M, Moore-Carrasco R, Argiles JM. Hemostasis alterations in metabolic syndrome. Int J Mol Med. 2006;18:969–974
  10. Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation. 2003;108:420–425
  11. Wallenfeldt K, Hulthe J, Fagerberg B. The metabolic syndrome in middle-aged men according to different definitions and related changes in carotid artery intima-media thickness (IMT) during 3 years of follow-up. J Intern Med. 2005;258:28–37
  12. Iannuzzi A, De Michele M, Bond MG, Sacchetti L, Fortunato G, Salvatore F, et al. Carotid artery remodeling in middle-aged women with the metabolic syndrome (from the ”Progetto ATENA” study). Am J Cardiol. 2005;96:1162–1165
  13. Wei YD, Hu DY, Zhang RF, Zheng LQ, Li J, Yu JM, et al. Metabolic syndrome complicated by peripheral arterial disease: clinical study of 2115 cases. Zhonghua Yi Xue Za Zhi. 2006;86:2114–2116
  14. Protack CD, Bakken AM, Xu J, Saad WE, Lumsden AB, Davies MG. Metabolic syndrome: a predictor of adverse events after carotid revascularization. J Vasc Surg. 2009;49:1172–1180
  15. Grundy SM, Brewer HBJ, Cleeman JI Conference Participants. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438
  16. Yutan E, Glickerman DJ, Caps MT, Hatsukami T, Harley JD, Davies MG. Percutaneous transluminal revascularization for renal artery stenosis: Veterans Affairs Puget Sound Health Care System experience. J Vasc Surg. 2001;34:685–693
  17. Sivamurthy N, Suroweic SM, Culakova E, Rhodes JM, Lee D, Sternbach Y, et al. Divergent outcomes after percutaneous therapy for symptomatic renal artery stenosis. J Vasc Surg. 2004;39:565–574
  18. Galaria II, Surowiec SM, Rhodes JM, Illig KA, Shortell CK, Sternbach Y, et al. Percutaneous and open renal revascularizations have equivalent long-term functional outcomes. Ann Vasc Surg. 2005;19:218–228
  19. Rundback JH, Sacks D, Kent KC, Cooper C, Jones C, Murphy TP, et al. Guidelines for the reporting of renal artery revascularization in clinical trials. Circulation. 2002;106:1572–1585
  20. Natali A, Pucci G, Boldrini B, Schillaci G. Metabolic syndrome: at the crossroads of cardiorenal risk. J Nephrol. 2009;22:29–38
  21. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  22. Einhorn D, Reaven GM, Cobin RH, Ford ES, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237–252
  23. Bloomgarden ZT. Definitions of the insulin resistance syndrome: the 1st World Congress on the Insulin Resistance Syndrome. Diabetes Care. 2004;27:824–830
  24. Executive Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  25. Lev-Ran A. Human obesity: an evolutionary approach to understanding our bulging waistline. Diabetes Metab Res Rev. 2001;17:347–362
  26. Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol. 2006;26:232–244
  27. Corpeleijn E, Bakker SJ, Stolk RP. Obesity and impaired renal function: potential for lifestyle intervention?. Eur J Epidemiol. 2009;24:275–280
  28. Kramer H, Luke A. Obesity and kidney disease: a big dilemma. Curr Opin Nephrol Hypertens. 2007;16:237–241
  29. Brevetti G, Schiano V, Sirico G, Giugliano G, Laurenzano E, Chiariello M. Metabolic syndrome in peripheral arterial disease: relationship with severity of peripheral circulatory insufficiency, inflammatory status, and cardiovascular comorbidity. J Vasc Surg. 2006;44:101–107
  30. Maksimovic M, Vlajinac H, Radak D, Marinkovic J, Jorga J. Relationship between peripheral arterial disease and metabolic syndrome. Angiology. 2009;60:546–553
  31. Zierler RE, Bergelin RO, Davidson RC, Cantwell-Gab K, Polissar NL, Strandness DEJ. A prospective study of disease progression in patients with atherosclerotic renal artery stenosis. Am J Hypertension. 1996;9:1055–1061
  32. Hoffmann R, Stellbrink E, Schröder J, Grawe A, Vogel G, Blindt R, et al. Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents. Am J Cardiol. 2007;100:1347–1352
  33. Canibus P, Faloia E, Piva T, Muçai A, Serenelli M, Perna GP, et al. Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation. Metabolism. 2008;57:593–597

 Competition of interest: none.

 The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a competition of interest.

PII: S0741-5214(09)01930-2

doi: 10.1016/j.jvs.2009.09.042

Journal of Vascular Surgery
Volume 51, Issue 4 , Pages 926-932 , April 2010

Article Tools

* Image Usage & Resolution